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Results: Acetylcholine efficacy [pEC50(acetylcholine)] for NG, DM,
DM+Met and DM+MP were 5.5(0.3), 4.7(0.6), 6.6(0.2) and 5.9(0.4)
respectively. Vascular reactivity of DM group was significantly de-
creased compared to NG group; while DM+Met and DM+MP groups
showed significant improvement in endothelium-dependent relaxation
compared to DM group. In vitro evaluation showed that MP maximal
relaxation [Emax(MP)] and efficacy [pEC50(MP)] were 94(24)% and
3.1(0.5) respectively. pEC50(MP) were significantly reduced after
incubation with elevated glucose [2.1(0.2)], L-NAME [2.4(0.2)] and
methylene blue [2.3(0.4)], respectively, implying vasodilation by MP is
endothelium-dependent involving nitric oxide-cGMP signaling path-
way. Emax(MP)was not affected by acute hyperglycemia [65.3(24.4)%].
Conclusion: MP possesses vasoprotective effect on aortic endothe-
lium in acute and chronic hyperglycemia. Vasomodulation by MP
is mediated through nitric oxide and its downstream transduction
mechanism. Future researches on vascular ion channels interaction,
cellular and molecular mechanisms of MP are warranted.
doi:10.1016/j.ijcard.2018.11.033
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Background: NT-proBNP is a useful biomarker in the manage-
ment of heart failure. However, there is conflicting evidence for the
prognostic value of NT-ProBNP in acute myocardial infarction (AMI).
Objectives:
(1) To explore the association between NT-proBNP and 1-year
cardiac related mortality in AMI patients.
(2) To explore the association between NT-proBNP and 1-year risk
of sudden cardiac death or ventricular arrhythmia, readmission
for heart failure, readmission for acute coronary syndrome
(ACS) and stroke.
Methods: We conducted a multicenter, prospective observational
study recruiting patients presenting with AMI between 1-August-
2016 to 31-January-2017, involving 1 cardiology referral center and
4 non-cardiology hospitals. NT-proBNP levels (Alere Triage®, US)
were measured within 24 hours of AMI diagnosis. Patients were
followed-up for 1 year.
Results: A total of 142 patients were recruited. Mean age was
55.5±10.2 years, 90.8% male and 63% were STEMI. The mean LVEF
was 50±14%. The NT-proBNP levels ranged from 20 to 16700 pg/ml,
with a median of 703 pg/ml. From the ROC curve, optimal cutoff
value for NT-proBNP of 1240 pg/ml was derived. Kaplan-Meier
survival analysis for the 1-year cardiac related mortality was sig-
nificantly higher for patients with NT-proBNP level of ≥1240 pg/ml
(3.1% vs. 18.2%; HR 6.32; 95%CI 1.68, 23.82; p=0.006). The 1-year
risk of sudden cardiac death or ventricular arrhythmia was also sig-
nificantly higher for patients with NT-proBNP level of ≥1240 pg/ml
(3.1% vs 13.6%; HR 4.63; 95%CI 1.16, 18.51; p=0.030). Readmission for
heart failure was also higher for patients with higher NT-proBNP level
(2.0% vs 15.9%; HR 8.42; 95%CI 1.75, 40.56; p=0.008). Readmission for
ACS and stroke were not associated with higher NT-proBNP levels
(pN0.5). Overall, patients with NT-proBNP level of ≥1240 pg/ml had
significantly higher all-cause mortality (4.1% vs 20.5%; HR 5.324; 95%CI
1.64, 17.30; pb0.001).
Conclusion: NT-proBNP is a useful point-of-care risk stratification
biomarker in AMI. A NT-proBNP level of ≥1240 pg/ml was associated
with significant higher risks of mortality, readmission for heart failure
and sudden death or ventricular arrhythmia.
doi:10.1016/j.ijcard.2018.11.034
4.
Cardiac Siderosis Severity Assessment Using CMR T2* Sequence
Among Transfusion-Dependent Thalassaemia Patients:
Experience in Hospital Seberang Jaya
Abu Sufian Ahmada, Noor Khairiah A. Karima, Rohayu Hamib,
Faraizah Abd Karimc, Mohamad Nazrulhisham Mad Naserd,
Mazeda Murade, Roslina Abd Halime
aRegenerative Medicine Cluster, Advanced Medical and Dental Institute,
Universiti Sains Malaysia, Bertam, Kepala Batas, Pulau Pinang, Malaysia
bLifestyle Science Cluster, Advanced Medical and Dental Institute, Universiti
Sains Malaysia, Bertam, Kepala Batas, Pulau Pinang, Malaysia
cTransfusion Medicine Unit, Pathology Department, Hospital Ampang, Selangor,
Malaysia
dCardiology Department, Hospital Pu/au Pinang, Pu/au Pinang, Malaysia
eRadiology Department, Hospital Seberang Jaya, Pu/au Pinang, Malaysia
Background: In Malaysia, approximately 40% of Thalassaemia
patients were dependent on regular blood transfusion for survival.
This treatment had rendered them susceptible to the complication of
cardiac siderosis. The prevalence of cardiac siderosis among these
patients in Malaysia has not been published despite the ever-
increasing demand to monitor it using cardiac magnetic resonance
imaging (CMR) T2* sequence.
Objective: The purpose of this study was to determine the
prevalence of cardiac siderosis in the northern part of peninsular
Malaysia and its association with other parameters that were used to
monitor iron overload and its complication: serum ferritin, liver T2*
and left ventricular ejection fraction (LVEF).
Methods: A retrospective single centred study was conducted
involving 1187 transfusion-dependent Thalassaemia patients who
were referred by multiple hospitals in northern region for CMR to
assess cardiac and liver iron status between January 2012 and May
2017. All enrolled patients had T2* sequence protocol performed on
a 1.5 Tesla Philips Achieva MR unit at Hospital Seberang Jaya which
was further analysed using CMR tools software. Demographic and
clinical information including relevant investigations pertaining to
iron overload assessment were recorded and statistical analysis was
performed.
Results: The prevalence of cardiac siderosis was 16.8%; 42.0%
was categorised as severe, 24.0% moderate and 34.0% mild. The mean
age (±SD) for those with cardiac siderosis was 20.9 (10.2) years
with male predominance. Beta thalassaemia major patients consti-
tuted most of the cardiac siderosis cases (57.0%). The mean (±SD)
serum ferritin, liver T2* and LVEF in these patients was 6249.05
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